# Talking Medicines

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/talking-medicines

- Industry: Healthcare IT
- Headquarters: Glasgow, UK
- Website: www.talkingmedicines.com
- Total disclosed funding: $2.3M
- Latest round: Series A (Nov 4, 2020)
- Investors on record: 3

## About

Talking Medicines Limited is a healthcare technology company specializing in AI-driven marketing solutions, transforming unstructured data into actionable insights for healthcare professionals.Founded in 2013 and headquartered in Glasgow, UK, Talking Medicines Limited focuses on leveraging AI technology to enhance healthcare marketing. The company was co-founded by Elizabeth Fairley, Jo Halliday, and Scott Crae, with Jo Halliday serving as the CEO. Talking Medicines has undergone strategic pivots to sharpen its focus on data-driven healthcare insights. The company has completed a total of 3 deals, with its most recent deal being a Grant funding round in February 2022, raising GBP 1.5 million from investors including SIS Ventures, Scottish Enterprise, Tern, and Thairm Bio, bringing the total amount raised to GBP 1.1 million.Talking Medicines specializes in AI-powered healthcare marketing solutions, with its flagship product being Drug-GPT. This product employs advanced data science techniques, including Artificial Intelligence (AI), Machine Learning (ML), and Natural Language Processing (NLP), to transform large volumes of unstructured conversational data into structured, actionable insights. Its primary use cases include message alignment, persona development, and audience intelligence, allowing healthcare agencies to derive nuanced insights from publicly sourced sentiment data. The solutions are designed to enhance data-driven decision-making during pre- and post-drug launch phases, targeting healthcare professionals and organizations that require precise data analysis. Talking Medicines serves a global client base, with a focus on markets in North America, Europe, and Asia, where there is a demand for advanced data intelligence in healthcare marketing.Talking Medicines generates revenue through B2B transactions, offering subscription-based access to its data intelligence platform, Drug-GPT. Clients, which include healthcare agencies and pharmaceutical companies, typically engage in yearly or multi-year contracts that provide them with access to tailored AI models and insights. These subscription plans are structured to cater to varying levels of data needs, enabling clients to choose options that best fit their operational requirements. The company focuses on building long-term partnerships with its clients, emphasizing the seamless integration of its services into existing marketing workflows, thus creating a sustainable revenue model based on continuous data support and updates.In February 2022, Talking Medicines received GBP 1.5 million in grant funding to support scaling operations and launching the PatientMetrx® technology platform, targeting expansion into the US pharmaceutical market. The company aims to develop new teams and agencies to better understand patient sentiments regarding their medications. These efforts are expected to enhance their existing services and meet the growing demands of healthcare agencies and professionals.

## Funding rounds

- Series A, Nov 4, 2020, $1.4M — Tern, Scottish Investment Bank
- Seed, Mar 15, 2019, $0.9M — SIS Ventures, Scottish Investment Bank

## Investors

- SIS Ventures (https://capitalatlas.ai/funds/sis-ventures) — Seed
- Scottish Investment Bank — Seed, Series A
- Tern (https://capitalatlas.ai/funds/tern) — Series A